Nasdaq Grants Continued Listing as Glucotrack Regains Equity Compliance
GCTK sits 52% above its 52-week low of $0.25 on light trading volume (0.1× avg).
Summary
The Nasdaq Hearings Panel granted Glucotrack's request for continued listing, subject to conditions, and confirmed the company has regained compliance with the stockholders' equity requirement. This removes an immediate delisting overhang that had been flagged in recent filings, including the Q2 10-Q filed August 14. The decision follows a reverse merger with Lokahi Therapeutics and multiple dilutive financings that strengthened the balance sheet. Management frames this as a milestone in its strategic transformation, though the company still faces going concern doubt and must meet all Nasdaq standards. The September 11 special meeting on the $50M equity line and bridge note conversion remains a key upcoming event.
At the time of this announcement, GCTK was trading at $0.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8M. The 52-week trading range was $0.25 to $14.14. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.